COMPASS Pathways PLC ADR (CMPS): Price and Financial Metrics


COMPASS Pathways PLC ADR (CMPS): $32.62

0.34 (+1.05%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CMPS Stock Price Chart Interactive Chart >

Price chart for CMPS

CMPS Price/Volume Stats

Current price $32.62 52-week high $61.69
Prev. close $32.28 52-week low $29.31
Day low $31.87 Volume 239,600
Day high $32.90 Avg. volume 407,119
50-day MA $33.32 Dividend yield N/A
200-day MA $39.24 Market Cap 1.36B

COMPASS Pathways PLC ADR (CMPS) Company Bio


COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin formulation that is in Phase IIb clinical trial to treat patients with treatment-resistant depression. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is based in Cheshire, the United Kingdom.


CMPS Latest News Stream


Event/Time News Detail
Loading, please wait...

CMPS Latest Social Stream


Loading social stream, please wait...

View Full CMPS Social Stream

Latest CMPS News From Around the Web

Below are the latest news stories about COMPASS Pathways plc that investors may wish to consider to help them evaluate CMPS as an investment opportunity.

COMPASS Pathways to participate in upcoming Maxim and Cantor investor conferences

London, UK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in two upcoming investor conferences as follows: Maxim Group and M-Vest Mental Health Advances in Mental Health, Psychedelics and Non-Psychedelics Virtual Conference: “Clinics and Commercialization: Scaling psychedelics to meet the needs of the menta

Yahoo | September 21, 2021

Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial

AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares launched the country’s first actively managed ETF covering the psychedelics sector. The AdvisorShares Psychedelics ETF (NYSE: PSIL), launched on the NYSE Arca market, providing exposure to biotechnology, pharmaceutical and life sciences companies that the firm deems are “leading the way in this nascent industry.” So far, this is the third ETF covering the psychedelics sector in North America. Th

Yahoo | September 20, 2021

Is the Options Market Predicting a Spike in COMPASS Pathways (CMPS) Stock?

Investors need to pay close attention to COMPASS Pathways (CMPS) stock based on the movements in the options market lately.

Yahoo | September 20, 2021

Journey Clinical raises $3M to allow psychotherapists to prescribe psychedelics TechCrunch

Psychedelics companies are all the rage right now. Compass Pathways is working with the magic mushroom compound psilocybin to treat depression. Its has raised $290 million in total. Atai Life Sciences backed by PayPal co-founder Peter Thiel brought in $258 million from its IPO. In the tech space, this has not gone unnoticed []

TechCrunch | September 17, 2021

Journey Clinical raises $3M to allow psychotherapists to prescribe psychedelics

Psychedelics companies are all the rage right now. Compass Pathways is working with the magic mushroom compound psilocybin to treat depression. Its has raised $290 million in total. Atai Life Sciences backed by PayPal co-founder Peter Thiel brought in $258 million from its IPO. In the tech space, this has not gone unnoticed []

TechCrunch | September 17, 2021

Read More 'CMPS' Stories Here

CMPS Price Returns

1-mo -1.24%
3-mo -2.60%
6-mo -6.13%
1-year -11.24%
3-year N/A
5-year N/A
YTD -31.53%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0767 seconds.